Although I did not mind the Friday PR, I don't think a PR was necessary for a botched call with 100 people...most of whom were already longs or bashers. If our hopes are pinned on PR's to keep our stock afloat selling now would be a good idea.

Solid product with proper management will get the stock to where we hope it goes despite daily volatility. PR's are nice updates, but not a foundation for stock price(unless they truly affect fundamentals of course like licensing deals).

If it gives the bashers more fodder, doesn't bother me at all. Is it a bad look for the company and its management? Yes. Does it change the fundamentals of if the product works? No. Did Vyera(hiv) pull out of the deal because of the call? No. Does it stop China(cancer/coronavirus), Canada and Japan(Gvhd) from potentially signing licensing deals with us. Nope.

A true PR mishap would be a lawsuit against our patents, or finding out all the HIV/Cancer data was fake, illegal activity, or a bad batch of drugs etc... things that would truly hinder revenue and the company moving forward. A botched call isn't one of them.

Unfortunately with a small nonrevenue biotech things have to go pretty well for everything to fall into place. We can't have too many moves that waste a lot of money we don't have (aka hiring Pestell).

Thus the risk we all still take by being long. We believe the product is solid, and take the CEO at face value(for the most part except for BLA timelines). In the end we shall see. I like our chances, but watch carefully, no OTC stock is a set it and forget it.